{"id":29338,"date":"2025-08-04T08:04:13","date_gmt":"2025-08-04T08:04:13","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/anbogen-receives-fda-clearance-to-initiate-phase-1-2-trial-of-abt-301-triplet-therapy-for-advanced-colorectal-cancer\/"},"modified":"2025-08-04T08:04:13","modified_gmt":"2025-08-04T08:04:13","slug":"anbogen-receives-fda-clearance-to-initiate-phase-1-2-trial-of-abt-301-triplet-therapy-for-advanced-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=29338","title":{"rendered":"Anbogen Receives FDA Clearance to Initiate Phase 1\/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer"},"content":{"rendered":"

TAIPEI<\/span><\/span>, Aug. 4, 2025<\/span><\/span> \/PRNewswire\/ — Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1\/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC).<\/p>\n

This open-label, multi-center international study plans to enroll 66 patients with proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mCRC to evaluate the safety and preliminary efficacy of the triplet therapy. Enrollment is planned in Taiwan<\/span> and Australia<\/span>. Tislelizumab, a PD-1 monoclonal antibody, used in this trial is provided by BeOne Medicines (formerly known as BeiGene). Further details on this collaboration were disclosed by Anbogen in a press release dated September 27, 2024<\/span>.<\/p>\n

ABT-301 is an oral HDAC1\/2\/3 inhibitor. Preclinical studies have shown that it promotes CD8+ cytotoxic T cell infiltration and activity, enhances antigen presentation, and inhibits M-MDSCs cells, effectively modulating the tumor microenvironment and converting “cold tumors” into “hot tumors” to improve the efficacy of immune checkpoint inhibitors. ABT-301 also exhibits pro-apoptotic, anti-angiogenic, and tumor metabolic regulation effects. As a single-molecule, multi-modality anti-cancer agent, ABT-301 aims to enhance tumor treatment when combined with the two antibody drugs.<\/p>\n

Notably, in a previous Phase 1 monotherapy clinical trial involving 23 participants, ABT-301 did not exhibit neutropenia or cardiac toxicity, which are commonly observed in other HDAC inhibitors\u2014further supporting its suitability for use in combination immunotherapy.<\/p>\n

Approximately 95% of mCRC patients are pMMR or non-MSI-H types\u2014commonly referred to as “cold tumors”\u2014which respond poorly to current immunotherapies. Only around 5% of patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) “hot tumors” typically benefit from immune checkpoint inhibitors. According to GlobalData, an estimated 370,000 new pMMR\/non-MSI-H patients in second-line or later settings are diagnosed annually across the U.S., China<\/span>, Japan<\/span>, and the top five European markets (UK, France<\/span>, Germany<\/span>, Spain<\/span>, and Italy<\/span>), representing a potential market size of USD $9 billion<\/span>.<\/p>\n

Anbogen stated that the FDA’s IND approval marks a key milestone in the development of ABT-301, demonstrating the safety profile of the triplet therapy and advancing it into clinical stages. The company emphasized that the study targets the majority of patients (over 90%) with poor responses to immunotherapy, aiming to provide a novel treatment option and address this unmet clinical need.<\/p>\n

Looking ahead, Anbogen will continue to advance the clinical development of ABT-301 while pursuing global licensing and strategic partnerships to accelerate commercialization and market entry. The company is also launching its Series B fundraising to attract strategic partners committed to advancing innovative cancer therapies and global expansion.<\/p>\n

About Anbogen Therapeutics<\/b><\/p>\n

Anbogen Therapeutics is a clinical-stage biotechnology company committed to developing precision oncology therapies that improve the lives of cancer patients worldwide. The company currently has two core assets:<\/p>\n

ABT-301, a HDAC1\/2\/3 inhibitor with immune-modulating capabilities, enhances the tumor microenvironment and boosts immune responses. It significantly improves the efficacy of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC), offering a new treatment pathway for the majority of patients who do not benefit from ICIs.<\/p>\n

ABT-501 is a novel Peptide Drug Conjugate (PDC) that targets LHRH-receptor tumors using a proprietary delivery system. It has shown strong efficacy and safety in triple-negative breast cancer models, with potential for broader cancer applications.<\/p>\n

For more information, please visit Anbogen’s official website at www.anbogen.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

TAIPEI<\/span><\/span>, Aug. 4, 2025<\/span><\/span> \/PRNewswire\/ — Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1\/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC).<\/p>\n

This open-label, multi-center international study plans to enroll 66 patients with proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mCRC to evaluate the safety and preliminary efficacy of the triplet therapy. Enrollment is planned in Taiwan<\/span> and Australia<\/span>. Tislelizumab, a PD-1 monoclonal antibody, used in this trial is provided by BeOne Medicines (formerly known as BeiGene). Further details on this collaboration were disclosed by Anbogen in a press release dated September 27, 2024<\/span>.<\/p>\n

ABT-301 is an oral HDAC1\/2\/3 inhibitor. Preclinical studies have shown that it promotes CD8+ cytotoxic T cell infiltration and activity, enhances antigen presentation, and inhibits M-MDSCs cells, effectively modulating the tumor microenvironment and converting “cold tumors” into “hot tumors” to improve the efficacy of immune checkpoint inhibitors. ABT-301 also exhibits pro-apoptotic, anti-angiogenic, and tumor metabolic regulation effects. As a single-molecule, multi-modality anti-cancer agent, ABT-301 aims to enhance tumor treatment when combined with the two antibody drugs.<\/p>\n

Notably, in a previous Phase 1 monotherapy clinical trial involving 23 participants, ABT-301 did not exhibit neutropenia or cardiac toxicity, which are commonly observed in other HDAC inhibitors\u2014further supporting its suitability for use in combination immunotherapy.<\/p>\n

Approximately 95% of mCRC patients are pMMR or non-MSI-H types\u2014commonly referred to as “cold tumors”\u2014which respond poorly to current immunotherapies. Only around 5% of patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) “hot tumors” typically benefit from immune checkpoint inhibitors. According to GlobalData, an estimated 370,000 new pMMR\/non-MSI-H patients in second-line or later settings are diagnosed annually across the U.S., China<\/span>, Japan<\/span>, and the top five European markets (UK, France<\/span>, Germany<\/span>, Spain<\/span>, and Italy<\/span>), representing a potential market size of USD $9 billion<\/span>.<\/p>\n

Anbogen stated that the FDA’s IND approval marks a key milestone in the development of ABT-301, demonstrating the safety profile of the triplet therapy and advancing it into clinical stages. The company emphasized that the study targets the majority of patients (over 90%) with poor responses to immunotherapy, aiming to provide a novel treatment option and address this unmet clinical need.<\/p>\n

Looking ahead, Anbogen will continue to advance the clinical development of ABT-301 while pursuing global licensing and strategic partnerships to accelerate commercialization and market entry. The company is also launching its Series B fundraising to attract strategic partners committed to advancing innovative cancer therapies and global expansion.<\/p>\n

About Anbogen Therapeutics<\/b><\/p>\n

Anbogen Therapeutics is a clinical-stage biotechnology company committed to developing precision oncology therapies that improve the lives of cancer patients worldwide. The company currently has two core assets:<\/p>\n

ABT-301, a HDAC1\/2\/3 inhibitor with immune-modulating capabilities, enhances the tumor microenvironment and boosts immune responses. It significantly improves the efficacy of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC), offering a new treatment pathway for the majority of patients who do not benefit from ICIs.<\/p>\n

ABT-501 is a novel Peptide Drug Conjugate (PDC) that targets LHRH-receptor tumors using a proprietary delivery system. It has shown strong efficacy and safety in triple-negative breast cancer models, with potential for broader cancer applications.<\/p>\n

For more information, please visit Anbogen’s official website at www.anbogen.com<\/a>.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-29338","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/29338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29338"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/29338\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}